AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
← KRAS / RAS targeting: from platform to Phase 3
#PANCREATICCANCER
11 people · 17 posts
Heat trend for this story
Heat now 3·Peak in the comparable set 4 (Apr 22 08:00)·Change over 24h in the comparable set –·Participants now 6
Participants counted6
Heat over time
Records
| Drug / trial | Readout | Setting |
|---|---|---|
| daraxonrasib ± GnPdaraxonrasib#PANCREATICCANCER#PDAC | mono ORR 47%; +GnP ORR 55%, DCR 90% | 1L mPDAC · Phase 1 |
Other cases in this chapter
- daraxonrasibmOS 13.2 vs 6.7 mo, HR 0.40
- zoldonrasibORR 52%, DCR 93%, mPFS 11.1 mo; ctDNA clearance 73%
- VS-7375NSCLC ORR 68.8% (n=16); pancreas ORR 58%
- elisrasibG12Ci-naive NSCLC ORR 59.5%; pretreated 32.3%
- RM-055Active in daraxonrasib-resistant and RAS-amplification models
Floor
x.com@ x.com@ x.com@ Memorial Sloan Kettering Cancer Center@MSKCancerCenter Anirban Maitra@Aiims1742 Memorial Sloan Kettering Cancer Center@MSKCancerCenter Anirban Maitra@Aiims1742 x.com@ M. Elisabeth@ChildrenNeedUs_ Another win for patients with pancreatic cancer.
x.com@ Ashish Manne@AshishManne Excited to present our posters at #AACR26.
x.com@ Ashish Manne@AshishManne From translational work yesterday to future-focused approaches today at #AACR26.
M. Elisabeth@ChildrenNeedUs_ Here’s a more compact & clear explanation of this study.
M. Elisabeth@ChildrenNeedUs_ Dr Balachandran is the lead researcher, the lead PI, of the pancreatic cancer mRNA study.
M. Elisabeth@ChildrenNeedUs_ OncUpdates@OncUpdates